Drug recall D-0248-2019
Product
ERBITUX CETUXIMAB Injection, 200 mg/100 mL (2 mg/mL), 100 mL per single-use vial, Rx only, Manufactured by: ImClone LLC, a wholly-owned subsidiary of Eli Lilly and Company, Branchburg, NJ 08876 USA. NDC: 66733-958-23
Reason for recall
Labeling: Missing label; potential for missing primary container label on the vial.
Lots and codes
Lot number: C1700167, exp 9/2020
Recall details
- Recalling firm
- Eli Lilly & Co, Indianapolis, IN
- Quantity
- 9,380 vials
- Distribution
- AL, AZ, CA, KS, LA, MS, OH, OR, TN, TX and Puerto Rico
- Type
- Voluntary: Firm initiated
- Recall initiated
- November 8, 2018
- Terminated
- April 22, 2020
Related products
- Erbitux – drug information
- NDC 66733-948 Erbitux · Cetuximab 2 mg/mL · ImClone LLC
- NDC 66733-958 Erbitux · Cetuximab 2 mg/mL · ImClone LLC